MARKSANS PHARMA LTD.

Marksans Pharma Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The exact date of the results declaration will be communicated separately. During this period, no trading in the company's shares is permitted for these individuals.

Marksans Pharma Ltd has resubmitted its financial results for the quarter and year ended March 31, 2026, in a machine-readable format after an initial submission on May 26, 2026, was deemed not to be in the required format by the NSE. The company stated that the oversight was unintentional and has assured that such an occurrence will be prevented in the future. The resubmission is in continuation of the 'Outcome of the Board Meeting' filing. The accompanying Independent Auditor's Report from MSKA & Associates LLP confirms that the standalone annual financial results are presented in accordance with SEBI Listing Regulations and provide a true and fair view.

Marksans Pharma Limited has successfully completed the acquisition of 100% share capital of QliniQ B.V., a Netherlands-based entity. This follows a prior intimation on June 1, 2026, and marks the finalization of the acquisition process. The company has officially recorded the completion of this strategic move.

Marksans Pharma Ltd. will acquire 100% of Netherlands-based QliniQ B.V. for €7.5 million in cash. QliniQ, a pharmaceutical and medical device company, reported revenue of €9.35 million and a net profit of €1.01 million for FY2025. The acquisition aims to strengthen Marksans' presence in European markets by leveraging QliniQ's established sales, marketing, and distribution capabilities.

Marksans Pharma Ltd's Board has recommended a final dividend of ₹0.90 per equity share (90% of face value of Re. 1) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). If approved, the dividend will be credited/dispatched within 30 days from the AGM date. The Board meeting was held on May 26, 2026, where the audited financial results for the quarter and year ended March 31, 2026, were also approved.

Marksans Pharma Ltd reported its FY26 financial results, achieving its highest-ever total income of approximately ₹3,033 crore, EBITDA of ₹601 crore (margin 20.4%), and PAT of ₹420 crore. The company saw growth driven by new launches across markets, including its Rx branded portfolio in Australia, and a strong recovery in the UK market. The US market also contributed with 112 new SKUs launched. Marksans expanded its global presence by entering new markets like Germany, Canada, and Ireland, and closed the year with a cash balance of approximately ₹990 crore.

Marksans Pharma Ltd. announced audited financial results for the quarter and year ended March 31, 2026. The Board of Directors recommended a final dividend of ₹0.90 per equity share of face value ₹1. The dividend, if approved at the AGM, will be credited/dispatched within 30 days. The Statutory Auditors, MSKA & Associates LLP, issued an unmodified opinion on the financial results.

Marksans Pharma Ltd's board meeting on May 26, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹0.90 per equity share of face value ₹1 each (90%) for the financial year 2025-26, subject to member approval at the AGM. The dividend will be credited/dispatched within 30 days from the AGM date. MSKA & Associates LLP issued an unmodified opinion on the audited financial results.

Marksans Pharma Ltd has scheduled a Board of Directors meeting on May 26, 2026, in Mumbai, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend on equity shares for the financial year 2025-26, if any. The trading window for dealing in the company's shares has been closed from April 1, 2026, and will remain closed until May 28, 2026.

Marksans Pharma Limited has received USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx). The product is bioequivalent and therapeutically equivalent to Pfizer Inc.'s Tessalon Capsules, 100 mg and 200 mg. Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.